For example, TP53 is one of the most frequently mutated genes in cancer, yet these mutations remain therapeutically challenging due to the diverse mechanisms of inactivation and the lack of universally targetable sites (Tian et al., 2019). This evidence concerns the gene TP53 and cancer.